Russell Alan J, the Chief Scientific Officer of Edgewise Therapeutics , Inc. (NASDAQ:EWTX), executed a series of stock transactions recently, as detailed in a recent SEC filing. On February 5 and 6, ...

Behrad Derakhshan, the Chief Business Officer of Edgewise Therapeutics , Inc. (NASDAQ:EWTX), recently sold 10,000 shares of the company's common stock. The shares were sold at an average price of $30.

Edgewise Therapeutics has a 12 month low of $9.61 and a 12 month high of $38.12. The firm has a fifty day simple moving average of $29.65 and a 200 day simple moving average of $26.09. Get ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...

Investors in Edgewise Therapeutics Inc (Symbol: EWTX) saw new options become available today, for the December 19th expiration. One of the key inputs that goes into the price an option buyer is ...

For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the share price soaring by 176%. Having said that, unprofitable companies are risky ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Edwards Lifesciences (EW – Research Report), Arvinas Holding ...

- Behrad Derakhshan, Ph.D. promoted to Chief Operating Officer (COO) - Robert Blaustein, M.D., Ph.D., Chief Development Officer, Edgewise Therapeutics (Photo ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...